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 Introduction 
 Iron deficiency anemia in totally gastrectomized pa-
tients has been described with a prevalence ranging be-
tween 15 and 54% according to patient selection, type of 
surgery, time after gastrectomy and presence of anemia 
before surgery  [1] .
 Due to the removal of both the gastric antrum and du-
odenum, and to frequent alkaline reflux, total gastrecto-
my can cause an irreversible modification of oral iron ab-
sorptive capabilities  [2] .
 Oral iron absorption may also be affected by the type 
of pharmaceutical preparation, in particular by the ionic 
state of iron salts administered. Iron, to be absorbed, 
must be in its ferrous form. Under normal conditions, a 
ferric reductase enzyme on the enterocyte brush border 
reduces ferric (Fe 3+ ) to ferrous (Fe 2+ ) iron; then, a pro-
tein called ‘divalent metal transporter 1’ transports iron 
across the enterocyte cell membrane into the cell. The 
alkaline environment, due to the reduced production of 
chloride acid and the absence of the duodenum – be-
lieved to be the primary site of iron absorption – could 
negatively influence the conversion from the trivalent to 
the bivalent form and therefore impair iron absorption 
 [3] .
 On the other hand, oral iron intake can be burdened 
by gastrointestinal side effects such as diarrhea, heart-
burn, abdominal pain, nausea and vomiting  [4] .
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 Abstract 
 Background: Iron deficiency anemia frequently occurs  in 
gastrectomized patients.  Methods: Serum iron levels follow-
ing the ingestion of a single oral dose of 105 mg elemental 
iron, taken as ferrous sulfate (FeS) or ferric gluconate (FeG), 
have been evaluated in 20 gastrectomized patients (and 
20 controls). All subjects participated on 2 different test days, 
1 month apart: they took a single dose of 105 mg elemen-
tal iron as FeS or FeG after a night of fasting. Serum iron con-
centrations at baseline, 30, 60, 120 and 180 min after the oral 
dose administration were measured.  Results: In patients and 
controls receiving FeG, serum iron levels did not significant-
ly change. After oral ingestion of FeS, patients’ serum iron 
levels gradually increased. The increase in serum iron lev-
els was 148 and 168% at 120 and 180 min in patients (p < 
0.0001 for both evaluations), whilst in controls, it was 216% 
at 120 min and 234% at 180 min, i.e. significantly higher than 
in gastrectomized patients (p < 0.001 for both evaluations). 
 Conclusions:  In gastrectomized patients, a single oral dose 
of FeS shows a significant increase in iron serum concentra-
tion, albeit lower than in controls. Further studies on a larger 
sample of patients will be necessary to confirm these results. 
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 For these reasons, in case of iron deficiency anemia, 
intravenous iron administration is often the preferred 
route for prompt iron storage replacement. Unfortunate-
ly, intravenous iron administration has been described 
related to the onset of possible hypersensitivity and aller-
gic reactions (with a rate of 0.8%) such as cutaneous rush, 
hives, generalized itch, headache, myalgia and serious 
anaphylactic reactions (with a rate of 0.04%)  [5] .
 It could be useful, in our opinion, to evaluate the re-
sidual oral iron absorptive capability of different pharma-
ceutical formulations in gastrectomized patients, also in 
order to tweak a simple and reliable test to identify poten-
tial candidates for oral iron administration.
 For the purpose of this study, FeS and FeG have been 
chosen because these are the oral iron formulations most 
frequently prescribed in Italy. In the scientific literature, 
FeS has been described as the best iron salt formulation 
recommended for oral administration, but it is available 
as tablets only. FeG is the second most frequently pre-
scribed iron salt formulation in Italy and is present as a 
solution for both oral and intravenous administration. 
FeG is widely used in its liquid form in patients with swal-
lowing difficulties.
 It was the aim of the study to compare the acute effects 
of two commercially available oral iron preparations of 
FeS and FeG on iron serum levels after a single dose in 
gastrectomized patients and controls.
 Patients and Methods 
 This single blind randomized  controlled study has been con-
ducted in 20 patients (11 males, 9 females, aged 49.7 ± 12.4 years) 
followed up after total gastrectomy at the Clinical Nutrition Unit of 
Federico II University Hospital in Naples and in 20 control subjects.
 All patients had received a Roux-en-Y gastrectomy (the median 
time after surgery was 28 months, range 8–120) due to gastric can-
cer (16 cases), gastric lymphomas (2 cases), caustic ingestion (1 
case) and gastric volvulus (1 case).
 All patients were considered disease free at the time of the 
study, in particular, those with anamnesis of oncological disease at 
the last follow-up performed 1–3 months before this study.
 Patients have been consecutively recruited during a routine fol-
low-up visit. None of them had received blood transfusions or in-
travenous iron during the 6 months prior to the study. In all pa-
tients, the presence of other conditions promoting anemia has 
been ruled out.
 The 20 healthy, age- and sex-matched controls have been re-
cruited among patients’ relatives or staff volunteers.
 All patients and controls gave their informed consent for par-
ticipation in the study, and the study protocol was approved by the 
local ethical committee.
 Patients’ clinical, anthropometric and demographic data are 
presented in  table 1 .
 Methods 
 All subjects participated on 2 test days 1 month apart, accord-
ing to a randomized protocol; they took a single dose of 105 mg 
elemental iron given as FeS (1 tablet) or FeG (7.5 ml in a vial) in 
the morning, after 12-hour overnight fasting.
 Blood samples were collected for serum iron concentration 
dosing at baseline and 30, 60, 120 and 180 min after taking the oral 
dose.
 Clinical and Laboratory Evaluation 
 Anthropometric measurements have been performed, and the 
body mass index was calculated as body weight (kg) divided by 
squared height (m 2 ).
 After 12-hour overnight fasting, before subjects ingested the 
iron dose, blood samples were collected for the determination of 
the following parameters: hemoglobin, mean corpuscular vol-
ume, serum iron, ferritin, transferrin, and total iron-binding ca-
pacity.
 All subjects took their oral dose at 9.00 a.m. in the experimental 
unit and continued to fast for 3 h; blood samples were collected at 
30, 60, 120 and 180 min after administration for serum iron dosing.
 The blood samples taken at 30, 60, 120 and 180 min after iron 
ingestion were collected from an antecubital vein into sterile tubes 
through an indwelling catheter. Samples for hemoglobin determi-
nation were collected in EDTA tubes, whilst samples for serum 
iron, transferrin and ferritin dosages were collected in serum sep-
arator tubes. All samples were sent to the laboratory for analysis. 
For hemoglobin analysis, a hematologic analyzer (ADVIA 2120, 
Siemens) was used; serum iron and ferritin levels were determined 
by spectrophotometry (Modular, Hitachi); in particular, for ferri-
tin dosage, an immunoenzymatic assay was used. Finally, for 
transferrin and total iron-binding capacity, a nephelometric meth-
od was used.
 Statistical Analysis 
 Data were digitized and analyzed with the SPSS 15 program. 
Means, standard deviations and frequencies were used as descrip-
tive statistics. Comparisons between groups were performed with 
the simple t test. Percent concentration change was calculated. Bi-
variate correlations were analyzed with the Pearson correlation 
test. Differences were considered significant with p values <0.05.
 Results 
 All patients had received total Roux-en-Y gastrectomy 
( fig. 1 ). Baseline hematochemistry results are reported in 
 table 1 .
 Two patients (10%) had baseline hemoglobin <12 g/dl 
and hematocrit <35%. Three patients (15%) had serum 
iron levels <60 μg/dl and 3 showed a mean corpuscular 
volume of <80 fl. Three patients had serum ferritin <20 
ng/ml, 5 patients between 20 and 50 ng/ml and 6 patients 
between 50 and 100 ng/ml.
 Baseline mean serum iron levels in patients and con-
trols were not significantly different ( table 1 ).
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 Administration of FeG 
 In patients receiving FeG, basal iron serum levels were 
97.5 ± 35.6 μg/dl and did not significantly change at 30 
(93.0 ± 34.9 μg/dl), 60 (93.8 ± 35.1 μg/dl), 120 (97.3 ± 35.2 
μg/dl) and 180 min (99.4 ± 37.3 μg/dl) after oral ingestion 
of 105 mg oral iron.
 Similarly, in controls receiving FeG, basal iron serum 
levels were 91.5 ± 25.9 μg/dl and did not significantly 
change at 30 (91.1 ± 27.9 μg/dl), 60 (96.9 ± 29.5 μg/dl), 
120 (100.9 ± 34.5 μg/dl) and 180 min (112.8 ± 41.5 μg/dl).
 Administration of FeS 
 Baseline serum levels of iron in patients receiving FeS 
were 92.4 ± 16.5 μg/dl and gradually increased to 98.3 ± 
15.2 μg/dl at 30 min (p < 0.0001), 110.4 ± 16.9 μg/dl at 60 
min (p < 0.0001), 137.2 ± 28.6 μg/dl at 120 min (p < 
0.0001) and 155.6 ± 37.0 μg/dl at 180 min (p < 0.0001). 
The increase in serum iron levels (ΔFe) was 148 and 168% 
at 120 and 180 min, respectively (p < 0.0001 for both eval-
uations).
 In controls receiving FeS, basal levels (96.1 ± 37.1 μg/
dl) gradually increased at 30, (115.1 ± 45.4 μg/dl; p < 
Table 1.  General characteristics and hematobiochemical data of patients and controls
Patients Controls p Normal range
Males/females 11/9 10/10 n.s.
Age, years 49.7±12.4 50.8±11.9 n.s.
Time for surgery, months 42±27 – n.s.
BMI, kg/m2 20.5±3.2 20.3±3.3 n.s. 18.5–25
WBC, n/μl 6,215±1,671 6,297±1,775 n.s. 4.8–10.8
RBC, ×106/μl 4,532±508 4,485±1,775 n.s. 4.0–5.6
Hemoglobin, g/dl 13.4±1.4 13.9±0.9 n.s. 12–16
Hematocrit, % 39.7±3.7 40.7±2.6 n.s. 35–48
MCV, fl 87.5±9.2 87.6±6.8 n.s. 80–97
Lymph, n/μl 2,005±919 1,885±956 n.s. 1.0–4.8
Platelets, ×103/μl 250±103 253±102 n.s. 130–400
Iron, μg/dl 89.9±29.6 92.4±26.5 n.s. 60–110
Ferritin, ng/ml 105.0±73.9 119.7±112.12 n.s. 5–150
Transferrin, g/l 2.7±0.5 2.6±0.4 n.s. 2.0–3.6
Transferrin saturation, % 25.1±8.4 27.2±7.9 n.s. 20–50
Protein, g/dl 7.2±0.5 7.3±0.6 n.s. 6.5–8.2
Albumin, g/dl 4.4±0.2 4.5±0.3 n.s. 3.6–5.2
Prealbumin, g/dl 0.2±0.3 0.2±0.2 n.s. 0.2–0.4
Cholesterol, g/dl 185±26 192±32 n.s.   <190
Pseudocholinesterase, U/l 7,619±1,938 8,912±2,123 n.s. 5,400–13,200
B12 vitamin, pg/ml 904±518 679±231 n.s. 190–866
Folate, ng/ml 15.86±4.9 12.3±3.7 n.s. 3.0–16.0
n.s. = Not significant; BMI = body mass index; WBC = white blood cells; RBC = red blood cells; MCV = mean 
corpuscular volume; Lymph = lymphocyte count.
Esophagojejunostomy
(esophagus joined to jejunum)
Esophagus
Duodenum
Bile
duct
Jejunum
Bile
 Fig. 1. Roux-en-Y reconstruction. After removal of the stomach 
and closure of the duodenal stump, end-to-side esophagojejunos-
tomy is performed. The second jejunal loop is divided: the aboral 
end is pulled up to the esophagus, while the oral end is sewn into 
the pulled-up limb, 50 cm distal to the esophagojejunal anastomo-
sis as an end-to-side jejunojejunostomy. 
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0.0001), 60 (157.2 ± 70.2 μg/dl; p < 0.0001), 120 (208.7 ± 
78.9 μg/dl; p < 0.0001) and 180 min (255.5 ± 67.9 μg/dl; 
p < 0.0001). ΔFe in controls was 216% at 120 min and 
234% at 180 min, i.e. significantly higher than in gastrec-
tomized patients, both at 120 and 180 min (p < 0.0001 for 
both evaluations) (fig. 2).
 There was no correlation between ΔFe at 120 and 180 
min and hemoglobin levels, as well as serum iron, trans-
ferrin and ferritin levels, both in patients and in controls.
 In conclusion, following the 3-hour test, both in pa-
tients and controls taking oral FeG, there were no signif-
icant differences in serum iron concentration at all time 
points, whilst iron serum levels were significantly in-
creased following the administration of FeS.
 None of the gastrectomized patients or controls expe-
rienced gastrointestinal and other side effects during the 
oral test.
 Discussion 
 Patients with gastrectomy may experience progressive 
blood hemoglobin decrease due to reduced iron absorp-
tion. Considering the impairment of oral absorption, in-
travenous iron formulations are prescribed worldwide in 
case of iron depletion, with some risks of serious compli-
cations  [6] .
 On the other hand, different iron intravenous prepara-
tions are available in different countries, in particular, 
iron sucrose is mainly prescribed in the USA, whilst in 
our country, the only intravenous formulation available 
is FeG, which is also administered orally.
 Our study evaluated the presence of residual intestinal 
iron absorption capacity in patients with total gastrecto-
my; for this purpose, the technique of serum iron moni-
toring after the administration of a single oral dose of dif-
ferent pharmaceutical iron preparations may result as a 
simple and reliable method  [7] . To avoid the effects of 
previous administrations and of cross-interferences of 
iron compounds, a 1-month washout interval between 
the testing days was observed.
 Patients have been compared with controls in order to 
evaluate residual iron absorption after gastrectomy but 
also to directly compare iron absorption of two different 
types of iron pharmaceutical preparations: FeS and FeG.
 In the present study, we decided to test the two most 
commonly prescribed oral iron formulations in Italy, FeS 
(as tablets or capsules) and FeG (in liquid form).
 In the scientific literature, FeS has been described as 
the best iron salt formulation recommended for oral ad-
ministration, but it is available as tablets only.
 FeG is the second most frequently prescribed iron salt 
formulation in Italy and is present as a solution for both 
oral and intravenous administration. FeG is widely used 
for its liquid form in patients with swallowing difficulties.
We had hypothesized that due to its liquid form, FeG 
could be more promptly absorbed than FeS tablets, as the 
latter require to be first broken up and then dissolved in 
gastroenteric juices; however, the findings of our study 
proved this hypothesis to be incorrect.
 A single oral dose of FeS shows a more favorable acute 
ΔFe than FeG in both gastrectomized patients and con-
trols.
 This finding can probably be explained by the different 
ionic form of the two compounds: in particular, FeS is a 
ferrous bivalent ion whilst FeG is a ferric trivalent form.
 Non-heme iron is known to be absorbed by entero-
cytes only in a bivalent form; consequently, trivalent iron 
requires reduction in the bivalent status before absorp-
tion.
 However, the present results confirm the findings of pre-
vious studies that showed that FeS, when compared with 
other compounds, leads to higher serum iron levels (i.e. 
better iron absorption) both in animals and humans  [8, 9] .
 To the best of our knowledge, there are no studies on 
FeG oral absorption other than those on intravenous ad-
ministration. Some studies on the oral absorption of FeG 
 [10–12] report a similar absorption to FeS. Unfortunate-
ly, FeG is not available in Italy.
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 Fig. 2. Mean serum iron levels following a single oral dose of 105 
mg elemental iron as FeS or FeG in patients and controls. Samples 
have been collected at 0, 30, 60, 120 and 180 min. Patients receiv-
ing FeS: p < 0.0001 at all time points. Controls receiving FeS: p < 
0.0001 at all time points. Patients receiving FeG: p ns at all time 
points. Controls receiving FeG: p ns at all time points. 
0 0 30 60
Time (min)
Ser
um
 iro
n l
eve
ls (
μg
/dl
)
120 180
50
100
150
200
250
300 Sulfate patients
Sulfate controls
Gluconate patients
Gluconate controls×
× × × × ×
D
ow
nl
oa
de
d 
by
: 
14
3.
22
5.
12
2.
21
9 
- 7
/2
6/
20
13
 1
1:
54
:2
5 
AM
 Iron Absorption in Patients with 
Gastrectomy  
Ann Nutr Metab 2013;63:55–59
DOI: 10.1159/000351447
59
 Our data strongly evidence the different acute re-
sponse of the two tested iron preparations, both in con-
trols and gastrectomized patients.
 In gastrectomized patients, the lack of gastric acid se-
cretion could influence the reduction of Fe 3+ to absorbable 
Fe 2+ , thus impairing the absorption of iron gluconate. Still, 
this is not the only reason, because iron gluconate does not 
appear absorbed in normal healthy controls either.
 Another study has compared oral absorption of iron 
sulfate with iron glycinate in gastrectomized patients, 
demonstrating a greater absorption of iron sulfate  [13] .
 FeG is an iron amino acid chelate and, in earlier stud-
ies, it has been demonstrated to be more bioavailable than 
FeS orally  [14] .
 In order to exclude possible factors potentiating the 
absorption, all consecutive gastrectomized patients have 
been recruited, irrespective of the presence or absence of 
anemia; moreover, we have administered the same dose 
for both products to compare the effects of the two com-
pounds.
 The presence of an acute iron serum concentration in-
crease after oral iron administration in gastrectomized 
patients could allow us to find a predictive test to identify 
patients responsive to oral iron supplementation.
 These data show the presence of acute absorption of 
FeS in totally gastrectomized patients, even though at a 
lower level than in control subjects. This finding, if con-
firmed on chronic dosing, could allow us to prescribe oral 
FeS compounds in gastrectomized patients, thus avoiding 
intravenous iron administration.
 In conclusion, gastrectomized patients seem to have 
residual oral acute iron absorption capacity, in particular 
when iron tablets are given as ferrous bivalent ion. There-
fore, the oral route could be considered to prevent or treat 
iron deficiency anemia early in these patients. Further 
studies on a larger scale and for longer periods of obser-
vation following oral iron administration are required to 
confirm the efficacy of long-term oral iron administra-
tion in gastrectomized patients.
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